

Angeion Corporation  
350 Oak Grove Parkway  
St. Paul, MN 55127 USA  
Telephone: (651) 484-4874  
Facsimile: (651) 484-4826



**FOR IMMEDIATE RELEASE**

## ***Angeion Corporation to Exhibit at MEDICA 2009***

**SAINT PAUL, Minn. (Nov. 5, 2009)** — Angeion Corporation (NASDAQ: ANGN) announced that it will be showcasing its flagship line of MedGraphics cardiorespiratory diagnostic systems at the MEDICA 2009 International Trade Fair. The event is taking place at the Messe Düsseldorf, November 18-21, 2009, in Düsseldorf, Germany.

At booth #10C06, Angeion will feature its new MedGraphics CPX Express®. This compact, easy-to-use system provides true breath-by-breath analysis of cardiorespiratory function during exercise on the most symptom-limited adult and pediatric patients to elite athletes. It is designed to meet the clinical and performance assessment needs of internal medicine, pulmonary, cardiology and sports medicine specialists.

“MEDICA is the world's largest annual forum for representatives calling on hospitals, clinics and physician offices in the health care industry. More than 135,000 participants from over 100 countries come to learn about current and future technologies and trends. We are extremely excited about exhibiting at MEDICA 2009—an event that gives us global exposure and the opportunity to showcase our full line of clinical solutions and latest diagnostic products,” said Rodney A. Young, President and Chief Executive Officer.

In addition to showcasing its broad line of cardiorespiratory products, Angeion will also preview its new MedGraphics AirTouch™ handheld spirometer featuring a touch screen display that simplifies operation and provides instantaneous feedback. The AirTouch™ will be offered in overseas markets and interfaces directly with MedGraphics extensive BreezeSuite™ software platform and database.

### **About Angeion Corporation**

Founded in 1986, Angeion Corporation acquired Medical Graphics Corporation in December 1999. Medical Graphics develops, manufactures and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MedGraphics ([www.medgraphics.com](http://www.medgraphics.com)) and New Leaf ([www.newleaffitness.com](http://www.newleaffitness.com)) brand and trade names. These cardiorespiratory diagnostic systems have a wide range of applications in healthcare as well as health and fitness. The Company's products are sold internationally through distributors and in the United States through a direct sales force that targets heart and lung specialists located in hospitals, university-based medical centers, medical clinics and physicians' offices, pharmaceutical companies, medical device manufacturers, clinical research organizations, health and fitness clubs, personal

training studios, and other exercise facilities. For more information about Angeion, visit [www.angeion.com](http://www.angeion.com).

The discussion above contains forward-looking statements about Angeion's future financial results and business prospects that by their nature involve substantial risks and uncertainties. You can identify these statements by the use of words such as "anticipate," "believe," "estimate," "expect," "project," "intend," "plan," "will," "target," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Our actual results may differ materially depending on a variety of factors including: (1) national and worldwide economic and capital market conditions; (2) continuing cost-containment efforts in our hospital, clinics, and office market; (3) our ability to successfully operate our business, including our ability to develop, improve, and update our cardiorespiratory diagnostic products and successfully sell these products under the MedGraphics and New Leaf brand names into existing and new markets; (4) our ability to maintain our cost structure at a level that is appropriate to our near to mid-term revenue expectations and that will enable us to increase revenues and profitability as opportunities develop; (5) our ability to achieve constant margins for our products and consistent and predictable operating expenses in light of variable revenues from our clinical research customers; (6) our ability to effectively manufacture and ship products in required quantities to meet customer demands; (7) our ability to expand our international revenue through our distribution partners and our Milan, Italy representative branch office; (8) our ability to successfully defend ourselves from product liability claims related to our cardiorespiratory diagnostic products and claims associated with our prior cardiac stimulation products; (9) our ability to defend our intellectual property; (10) our ability to develop and maintain an effective system of internal controls and procedures and disclosure controls and procedures; and (11) our dependence on third-party vendors. Additional information with respect to the risks and uncertainties faced by the Company may be found in, and the above discussion is qualified in its entirety by, the other risk factors that are described from time to time in the Company's Securities and Exchange Commission reports, including the Annual Report on Form 10-K for the year ended October 31, 2008.

Contact: William J. Kullback, SVP & Chief Financial Officer, (651) 766-3492

###